
Opinion|Videos|December 4, 2024
The Clinical and Economic Impact of LEMS in SCLC Care
Author(s)Wade Iams, MD
Key Takeaways
- Disparities in healthcare access can lead to delayed diagnosis and suboptimal treatment of LEMS in small cell lung cancer patients, affecting outcomes.
- Quantifying the economic burden of LEMS requires evaluating direct medical costs, indirect costs, and patient out-of-pocket expenses.
A medical expert discusses how disparities in health care access affect the management and outcomes of Lambert-Eaton myasthenic syndrome (LEMS) in patients with small cell lung cancer, how health care providers can quantify the economic burden of LEMS on both patients and health care systems, the role of patient-reported outcomes in providing deeper insights into the clinical and economic burden of LEMS, and how health systems can utilize real-world data to better understand the indirect costs of LEMS.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How do disparities in health care access affect the management and outcomes of Lambert-Eaton myasthenic syndrome (LEMS) in patients with small cell lung cancer?
- How can health care providers quantify the economic burden of LEMS on both patients and health care systems?
- In what ways can patient-reported outcomes provide deeper insights into the clinical and economic burden of LEMS?
- How can health systems utilize real-world data to better understand the indirect costs of LEMS?
Advertisement
Related to this article

Research at ObesityWeek 2026 tracks rising obesity in Medicare, productivity losses, prior authorization denials, and GLP-1 persistence.

In 459 patients with FLT3-ITD AML given high-dose anthracycline induction, a high allelic ratio was not linked to survival.

From 9.6 million US diabetic retinopathy cases to a new FDA warning on GLP-1s, here are 5 things to know about diabetic eye disease this November.

The action is based on phase 3 VOLGA results, which were presented at the ESMO Congress 2026. They support a perioperative regimen that limits the antibody-drug conjugate to 3 cycles before bladder removal.

New CMS data let EBRI measure what employer plans owe after No Surprises Act arbitration: $8.39B in 2025, though premium impact is unclear.

In this part 2, Kirsten Axelsen, MS, discusses racial disparities, AI in prior authorization, and payers’ readiness for the next wave of CLL therapies.

Kirsten Axelsen, MS, discusses gaps in biomarker testing, nonmedical barriers, and utilization management from a new report on access to CLL care.
Advertisement
Advertisement
Trending on AJMC
1
ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity's Costs
2
FDA Approves Durvalumab Plus EV Before Surgery in Cisplatin-Ineligible MIBC
3
MM’s Vulnerability to CAR T Was a Happy Surprise: Nikhil C. Munshi, MD
4
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
5


